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Abstract
Background: The shape of the dose-response curve at low doses differs from the linear quadratic
model. The effect of a radio-adaptive response is the centre of many studies and well known inspite
that the clinical applications are still rarely considered.
Methods: We studied the effect of a low-dose pre-irradiation (0.03 Gy – 0.1 Gy) alone or followed
by a 2.0 Gy challenging dose 4 h later on the survival of the HT29 cell line (human colorectal cancer
cells) and on the GM637 cell line (human fibroblasts).
Results: 0.03 Gy given alone did not have a significant effect on both cell lines, the other low doses
alone significantly reduced the cell survival. Applied 4 h before the 2.0 Gy fraction, 0.03 Gy led to
a significant induced radioresistance in GM637 cells, but not in HT29 cells, and 0.05 Gy led to a
significant hyperradiosensitivity in HT29 cells, but not in GM637 cells.
Conclusion: A pre-irradiation with 0.03 Gy can protect normal fibroblasts, but not colorectal
cancer cells, from damage induced by an irradiation of 2.0 Gy and the application of 0.05 Gy prior
to the 2.0 Gy fraction can enhance the cell killing of colorectal cancer cells while not additionally
damaging normal fibroblasts. If these findings prove to be true in vivo as well this may optimize the
balance between local tumour control and injury to normal tissue in modern radiotherapy.
Background
It is widely accepted that the shape of the dose-response
curve at low doses differs from the linear quadratic model
[1]. Induced radioresistance, hyperradiosensitivity or
adaptive responses (i.e. a biopositive effect induced by a
low priming dose and identified after application of a
higher challenging dose) may occur at low doses of irradi-
ation. The radio-adaptive response was first recognized
1984, when Olivieri et al. demonstrated that human lym-
phocytes exposed to low concentrations of radioactive
thymidine show fewer chromatid aberrations caused by a
1.5 Gy challenging dose than those not pre-exposed to
irradiation [2]. Several publications have studied the
effect with different cell lines, different pre-irradiation
doses, and variable challenging doses [3-10]. However,
the exact mechanism of the effect is yet unknown, thus
precluding predictions whether a cell line will show an
adaptive response or not. An altered gene expression
caused by low-dose ionizing radiation has been identi-
fied. A radio-adaptive response seems to be associated
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with an up-regulation of DNA repair and stress response
genes and a down-regulation of cell cycle control and
apoptosis genes. TP53 (Tumour Protein p53) is supposed
to play an important role in this mechanism [11]. Protein
synthesis, metabolism and signal transduction appear to
be involved in the adaptive response as well [9]. However,
controversy remains regarding the mechanism and role of
the adaptive response [12]. This is probably due to cell-
type and tissue-specific variations and different experi-
mental conditions [12,13].
Most radio-adaptive response experiments focussed on
basic research of this phenomenon, with only few studies
concentrating on its clinical applications, e.g. in radio-
therapy [14].
We had previously described a difference between the
reaction of normal bladder cells (HCV29) and that of
bladder cancer cells (RT4) to different adaptive doses of
irradiation. HCV29 cells showed an induced radioresist-
ance after pre-irradiation doses of 0.05 Gy or 0.1 Gy,
whereas RT4 cells displayed a hyperradiosensitivity after
pre-irradiation with 0.05 Gy, 0.1 Gy, 0.2 Gy or 0.5 Gy
[14].
While bladder cancer is only infrequently treated by radi-
otherapy, pre- or postoperative irradiation of stage II or III
colorectal cancer is very common. These tumours are
responsible for 655.000 deaths/year worldwide [15] with
an incidence of 88.3/100.000 men and of 84.9/100.000
women in Germany in 2002 [16]. Colorectal cancer is
thus one of the most common cancers after prostate can-
cer for men and breast cancer for women. It is therefore of
utmost importance to optimize the treatment for colorec-
tal cancer in order to attain a high cure rate and mini-
mized side effects. Radio-adaptive doses applied may
probably aid to achieve this end as an adjunct to standard
chemo-radiotherapy.
It was therefore our aim to evaluate the effect of different
pre-irradiation doses followed by a 2.0 Gy fraction on a
colorectal cancer cell line (HT29) and on normal fibrob-
lasts (GM637).
Methods
Cell culture
HT29 is a cell line derived from human colorectal cancer
cells [17], while GM637 is a cell line of human fibroblasts
[18].
Both cell lines were routinely grown in 80 ml flasks
(NUNC, Wiesbaden, Germany). For HT29 cells the
medium consisted of 83% McCoy's 5A medium supple-
mented with 16% fetal calf serum and 1% of a mixture of
antibiotics (104 IU penicilline/ml and 104 μg streptomy-
cin/ml). The medium for GM637 cells was a mixture of
82% minimum essential medium MEM (Eagle) with
Earle's salts, 25 mM HEPES and without L-glutamine, of
16% fetal calf serum, of 1% sodium pyruvate 100 mM and
of 1% of the antibiotic mixture (104 IU penicilline/ml and
104 μg streptomycin/ml). The cell lines were incubated at
37°C with 5% CO2, 95% humidity and a pH of 7.4. Cells
were passaged in the exponential growing phase once a
week, using 0.05% trypsin plus 0.02% EDTA in PBS at
37°C.
Experimental plating
96-well culture plates were used for all experiments. Cells
were seeded at a density of 250 cells per well (250 cells in
200 μl medium). Each plate contained wells with HT29
and wells with GM637, so that both cell lines were treated
in the exact same way. Additionally, another plate was
seeded with an increasing cell number per row (62.5-125-
250-500-750 cells per well) for cell growth monitoring
and survival reference.
Irradiation
After an incubation period of 24 h the plates were irradi-
ated with 0 Gy, 0.03 Gy, 0.05 Gy or 0.1 Gy at a dose rate
of 0.03 Gy/min (225 kV, 5 mA, 0.35 mm Cu). 4 h after
pre-irradiation cells were further irradiated with 0 Gy or
2.0 Gy at a dose rate of 1.0 Gy/min (225 kV, 15 mA, 0.35
mm Cu). As a result, eight different irradiation groups
were evaluated: 0 Gy (control), 0.03 Gy alone, 0.05 Gy
alone, 0.1 Gy alone, 2.0 Gy alone, 0.03 Gy plus 2.0 Gy,
0.05 Gy plus 2.0 Gy and 0.1 Gy plus 2.0 Gy.
We chose the pre-irradiation doses to be 0.03 Gy, 0.05 Gy
and 0.1 Gy respectively following an earlier study [14]
that demonstrated pre-irradiation doses of 0.05 Gy and
0.1 Gy, but not of 0.5 Gy to be effective.
Cell viability test
The plates were incubated for an additional 7 days. The
medium was subsequently removed from all wells. Cells
were washed with PBS and 100 μl medium with 10%
WST-1 (tetrazolium salt 4- [3-(4-iodophenyl)-2-(4-nitro-
phenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) were
added to all wells. WST-1 is cleaved to a water-soluble for-
mazan dye whose amount directly correlates to the
number of metabolically active cells and is quantified
spectrophotometrically by an ELISA reader at a wave-
length of 450 nm (reference wavelength: 690 nm). The
optical density was measured immediately (background
measurement) and after 3 h.
Result analysis
All experiments were repeated three times resulting in at
least 55 single data sets per irradiation group and cell line.
The standard curve for control cells was checked to be cer-Radiation Oncology 2008, 3:12 http://www.ro-journal.com/content/3/1/12
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tain that the cells of the experimental plates are in the
exponential phase of the survival curve and not in the pla-
teau phase. After subtracting the background the relative
cell survival of all wells was calculated. Using the Stu-
dent's t-test the statistical significance of the results (p ≤
0.05) was evaluated.
Results
HT29 cell studies
An irradiation with 0.05 Gy (p = 0.000002) and 0.1 Gy (p
= 0.000136) led to a significantly lower cell survival in
HT29 cells, whereas HT29 cells irradiated with 0.03 Gy
did not show a significant decrease in cell survival, when
compared to the control group (Table 1).
The adaptive response experiments, i.e. the experiments
performed with a pre-irradiation followed by a 2.0 Gy
irradiation, did not demonstrate a significant induced
radioresistance. The 0.05 Gy pre-irradiation dose even led
to a significantly decreased cell survival (p = 0.012249).
(Table 2).
GM637 cell studies
An irradiation dose of 0.03 Gy (p = 0.711896) alone did
not result in a significantly lower cell survival of GM637
cells, while irradiation doses of 0.05 Gy (p = 0.000003)
and 0.1 Gy (p = 0.008301) led to a significantly reduced
cell survival (Table 3).
Pre-irradiation doses of 0.03 Gy (p = 0.002591) or 0.1 Gy
(p = 0.044575) applied 4 h prior to the 2.0 Gy fraction led
to a significantly enhanced cell survival in GM637 cells,
when compared to cells irradiated with 2.0 Gy alone.
These pre-irradiation doses therefore led to an induced
radioresistance in GM637 cells. This effect was most pro-
nounced in the 0.03 Gy experiment. A pre-irradiation of
0.05 Gy led to a slightly increased radioresistance, which
was not statistically significant however (p = 0.429477).
(Table 4).
HT29 and GM637 cell studies in comparison
An irradiation with 0.03 Gy alone did not have a signifi-
cant effect on the survival of HT29 and GM637 cells,
whereas 0.05 Gy and 0.1 Gy led to a significantly lower
cell survival in both cell lines.
The effect of the various pre-irradiation doses applied 4 h
prior to the 2.0 Gy fraction varied between HT29 and
GM637 cells. Pre-irradiation doses of 0.03 Gy and 0.1 Gy
induced a significant radioprotective effect in GM637
fibroblasts, but not in HT29 colorectal carcinoma cells. A
pre-irradiation dose of 0.05 Gy led to a significantly lower
cell survival in HT29 cells, and a slightly, not significantly,
higher survival in GM637 cells. A pre-irradiation with
0.03 Gy seems to therefore protect normal fibroblasts, but
not colorectal cancer cells, from radiation-induced dam-
age, while an adaptive dose of 0.05 Gy can lead to a
reduced survival of colorectal cancer cells, but not of nor-
mal fibroblasts.
Discussion
Modern radiotherapy uses sophisticated techniques to
optimize therapeutic tumour control. Side effects on nor-
mal tissues, however, are the single most limiting factor to
the therapy. Therefore research in the field of radiation
oncology not only needs to focus on maximizing tumour
destruction but also on minimizing side effects on normal
tissues.
The results of our studies imply that a low-dose pre-irradi-
ation applied 4 h prior to the main irradiation may either
cause a reduction of the side effects of radiotherapy of
colorectal carcinomas on normal tissues or allow
enhanced tumour cell killing while not leading to addi-
tional side effects – provided that our findings prove to be
true in vivo as well.
Table 1: Descriptive statistical parameters of the experiments 
on the effect of different low irradiation doses alone on HT29 
cells
Irradiation dose Mean survival Standard deviation p-Value
0 Gy 0.784 0.148 -
0.03 Gy 0.736 0.101 0.367357
0.05 Gy 0.508 0.052 0.000002*
0.1 Gy 0.604 0.036 0.000136*
* statistically significant
Table 2: Descriptive statistical parameters of the experiments 
on the effect of different pre-irradiation doses plus 2.0 Gy on 
HT29 cells
Irradiation dose Mean survival Standard deviation p-Value
2.0 Gy 0.501 0.023 -
0.03 Gy + 2.0 Gy 0.551 0.044 0.066972
0.05 Gy + 2.0 Gy 0.434 0.025 0.012249*
0.1 Gy + 2.0 Gy 0.527 0.033 0.288153
* statistically significant
Table 3: Descriptive statistical parameters of the experiments 
on the effect of different low irradiation doses alone on GM637 
cells
Irradiation dose Mean survival Standard deviation p-Value
0 Gy 0.785 0.116 -
0.03 Gy 0.804 0.123 0.711896
0.05 Gy 0.539 0.053 0.000003*
0.1 Gy 0.659 0.084 0.008301*
* statistically significantRadiation Oncology 2008, 3:12 http://www.ro-journal.com/content/3/1/12
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In our experiments, 0.03 Gy by itself did not have a signif-
icant effect on cell survival, neither on the tumour (HT29)
nor on the normal cell line (GM637). When this dose is
applied as a pre-irradiation dose it may induce a signifi-
cant radioprotective effect in GM637 human fibroblasts,
but not in HT29 colorectal cancer cells. Provided that this
phenomenon not only exists in vitro, but also in vivo, and
that our cell model reflects real tissue conditions, and
moreover exerts its effect for several dose fractions,
reduced side effects may be achieved for radiotherapy of
colorectal cancer. Using an adaptive dose to protect nor-
mal tissue may allow a dose escalation to result in a
destruction of more tumour cells. In that case, a better
downstaging may theoretically be achieved thus allowing
more radical resections. The addition of a daily dose of
0.03 Gy to the conventional 1.8 Gy or 2.0 Gy fractions
would add no more than 0.9 Gy to the total irradiation
dose applied in approx. 30 sessions.
Hints for an alternative possible application of pre-irradi-
ation doses in radiotherapy of colorectal cancer might
result from our experiments, as well. A pre-irradiation
dose of 0.05 Gy led to a significantly lower cell survival in
HT29 cells, and a slightly, not significantly, higher sur-
vival in GM637 cells. When an adaptive dose of 0.05 Gy
can lead to a reduced survival of colorectal cancer cells,
but not of normal fibroblasts, the pre-irradiation can help
to improve tumour cell killing in cancer therapy while not
adding more side effects.
Clinical studies are, however, needed to evaluate whether
this assumptions holds true in a clinical setting.
In our study, we have concentrated on the commonly
known doses for radio-adaptive response experiments.
We have therefore not used a pre-irradiation dose of less
than 0.03 Gy. As we demonstrated the pre-irradiation
dose of 0.03 Gy to be effective to induce radioresistance in
normal fibroblasts, it remains to be investigated, however,
whether a dose below 0.03 Gy may also lead to the above
mentioned effects.
Lambin et al. demonstrated HT29 cells to be hypersensi-
tive to low radiation doses. While the cell survival
response showed a good fit to the linear quadratic model
for 2 to 5 Gy, it demonstrated a hyperradiosensitivity for
0.05-0.3 Gy and an induced radioresistance for 0.3-1.0 Gy
[19]. This is consistent with our findings that HT29 cells
show a significantly lower survival when irradiated with
0.05 Gy or 0.1 Gy alone. A dose of 0.03 Gy was not tested
by Lambin et al.. In our experiments 0.03 Gy alone did
not have a significant effect on the survival of HT29 cells.
Cell lines known to be relatively radioresistant, e.g. HT29
cells (colorectal cancer) and RT4 cells (bladder cancer),
often demonstrate a hyperradiosensitive reaction to low
irradiation doses [14,20,21]. It remains to be clarified,
whether this hyperradiosensitivity is an independent
effect or whether it represents the absence of induced radi-
oresistance [20]. The induction of PBP74/mortalin/
Grp75, a member of the hsp 70 family, seems to play a
role in induced radioresistance in HT29 cells [6].
A radio-adaptive response can be measured in terms of
cell survival – as performed in our study -, of reduction of
chromosomal aberrations, of micronuclei formation or of
mutations [3,22-24]. It occurs after pre-irradiation doses
of 0.01 Gy [4] to 1.5 Gy [3] depending on the cell line
examined and on the experimental conditions. In our
study, we observed a radio-adaptive response in GM637
cells for 0.03 Gy and 0.1 Gy pre-irradiation doses. The
time span of 4 h between pre-irradiation and the challeng-
ing dose has been used in the past [25], however, other
intervals have been studied as well with differing results
[26].
The mechanism of the adaptive response is still not com-
pletely understood, but it is widely accepted that induci-
ble DNA repair mechanisms play an important role [27],
whereas others believe in decreased damage fixation [28].
Furthermore, stress response, apoptosis pathways, signal
cascades, DNA conformation changes, chromosome
organization, bystander effects and cell cycle control are
probably involved as well [1,29-33]. Protein synthesis
appears to be essential for the induction of an adaptive
response [5] and several genes have been identified that
play a crucial role in this phenomenon [6-10]. Recent
publications pointed out the role of the MAPKs p38 and
ERK1/2 [34], NF-κB [35] and activation of Raf and Akt
[36]. It is proposed that the radio-adaptive response fol-
lows mainly from mutations at the base-sequence level,
not the chromosome level, [37] and involves some com-
ponents of the nucleotide excision repair pathway [38].
Adaptive and bystander response are presumably linked
via reactive oxygen and nitrogen species [39].
Table 4: Descriptive statistical parameters of the experiments 
on the effect of different pre-irradiation doses plus 2.0 Gy on 
GM637 cells
Irradiation dose Mean survival Standard deviation p-Value
2.0 Gy 0.421 0.027 -
0.03 Gy + 2.0 Gy 0.516 0.049 0.002591*
0.05 Gy + 2.0 Gy 0.449 0.057 0.429477
0.1 Gy + 2.0 Gy 0.479 0.037 0.044575*
* statistically significantRadiation Oncology 2008, 3:12 http://www.ro-journal.com/content/3/1/12
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Further experiments will be needed to completely eluci-
date the mechanism of the adaptive response. In addition,
potential clinical applications of the adaptive response
need to be studied as well. Our data and previous studies
suggest normal and tumour cells to react differently to low
pre-irradiation doses. While bladder cancer cells show a
hyperradiosensitivity, normal bladder cells demonstrate
an induced radioresistance [14].
Conclusion
In conclusion, we demonstrated a pre-irradiation with
0.03 Gy to protect human fibroblasts (GM637) but not
colorectal cancer cells (HT29) from radiation induced
damage of a subsequent 2.0 Gy challenging dose and the
application of 0.05 Gy prior to the 2.0 Gy fraction to
enhance the cell killing of colorectal cancer cells while not
additionally damaging normal fibroblasts. If these find-
ings prove to be true in vivo as well this confirms the
hypothesis that low pre-irradiation doses may optimize
the balance between local tumour control and injury to
normal tissue in modern radiotherapy of colorectal can-
cer, one of the most common neoplasms world-wide.
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